Collectively, our results demonstrating changes in activation of ERBB3 upon DARPP-32 modulation in the presence of EGFR TKI support a model in which DARPP-32 contributes to ERBB3-driven “bypass signaling” to promote EGFR-mutated NSCLC cell survival. This evidence concerns the gene EGFR and non-small cell lung carcinoma.